FAQ
Have questions? We’re here to help answer. Feel free to reach out for more information.
Based on robust research from multiple randomized trials early visualization and identification of atherosclerotic plaque in patients with chest pain allows early therapy and decreases myocardial infarction or cardiovascular death by 41-70%.
No. Since the chest pain guidelines changed in 2021, coronary CTA is the only Class 1 noninvasive test with Level A evidence for diagnosing CAD and guiding decisions. Going forward, insurance carriers would prefer one most accurate test instead of layered testing that increases cost, radiation and potentially exposes the patient to unnecessary invasive testing.
Yes. With new technologies such as CT Fractional flow reserve (CT FFR) we can now obtain additional functional data that provide information about blood flow and hemodynamic significance of lesions seen on coronary CTA. This data is extracted from the same CT dataset without need for additional imaging or radiation. In addition, some software can provide plaque analysis that can further guide medical decisions.
